Abstract: Each arterial bifurcation lesion has a fingerprint-like pattern related to varying amounts of plaque and degree of obstruction in the main vessel proximal to, within the bifurcation itself, and the distal limbs of the main branch and side branch(es) and related to the angle of the bifurcation. A new device and with it a new technique is described to optimize treatment of bifurcation (and trifurcation) lesions. The invention and related method use a catheter capable of delivering two or more guide wires exiting at the distal end of the catheter allowing treatment of lesions more safely and efficaciously. Safety is increased by allowing both guide wires to remain in place throughout the entire procedure. Efficacy is increased, particularly in the long-term, by providing a result that maximizes vessel coverage and normal flow dynamics in the entire bifurcation area.

Abstract: The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a ?2 adrenergic receptor agonist (?2-AR agonist) and a vasodilator can be used in treating reperfusion injury.

Abstract: Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising a protein kinase A (PKA) activator and a ?1-adrenergic receptor antagonist sufficient to reduce reperfusion injury to an ischemic tissue.

Abstract: Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising a protein kinase A (PKA) activator and a ?1-adrenergic receptor antagonist sufficient to reduce reperfusion injury to an ischemic tissue.

Abstract: The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a ?2 adrenergic receptor agonist ?2-AR agonist) and a vasodilator can be used in treating reperfusion injury.

Abstract: Each arterial bifurcation lesion has a fingerprint-like pattern related to varying amounts of plaque and degree of obstruction in the main vessel proximal to, within the bifurcation itself, and the distal limbs of the main branch and side branch(es) and related to the angle of the bifurcation. A new device and with it a new technique is described to optimize treatment of bifurcation (and trifurcation) lesions. The invention and related method use a catheter capable of delivering two or more guide wires exiting at the distal end of the catheter allowing treatment of lesions more safely and efficaciously. Safety is increased by allowing both guide wires to remain in place throughout the entire procedure. Efficacy is increased, particularly in the long-term, by providing a result that maximizes vessel coverage and normal flow dynamics in the entire bifurcation area.

Abstract: Disclosed is method for reducing myocardial cell damage during and/or after percutaneous coronary intervention in a subject's coronary artery. The method includes instilling a beta blocker directly into the subject's coronary artery prior to percutaneous coronary intervention. A kit for carrying out percutaneous coronary intervention is also disclosed. The kit includes a catheter and a beta blocker.

Abstract: Disclosed is method for reducing myocardial cell damage during and/or after percutaneous coronary intervention in a subject's coronary artery. The method includes instilling a beta blocker directly into the subject's coronary artery prior to percutaneous coronary intervention. A kit for carrying out percutaneous coronary intervention is also disclosed. The kit includes a catheter and a beta blocker.